JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
131.65
+1.54 (+1.18%)
At close: 4:00PM EDT

131.65 0.00 (0.00%)
After hours: 6:48PM EDT

Stock chart is not supported by your current browser
Previous Close130.11
Open131.00
Bid131.20 x 1400
Ask131.97 x 1300
Day's Range130.29 - 132.00
52 Week Range121.00 - 148.99
Volume11,063,023
Avg. Volume7,291,306
Market Cap346.646B
Beta (3Y Monthly)0.73
PE Ratio (TTM)21.87
EPS (TTM)6.02
Earnings DateOct 15, 2019
Forward Dividend & Yield3.80 (2.92%)
Ex-Dividend Date2019-08-26
1y Target Est149.35
Trade prices are not sourced from all markets
  • This new organic baby food will be on Whole Food shelves today
    Yahoo Finance Video

    This new organic baby food will be on Whole Food shelves today

    Cerebelly is a new baby food going up against big competitors. Yahoo Finance's Julie Hyman and Adam Shapiro discuss with Jennifer Zeszut -Cerebelly CEO and Dr. Teresa Purzner - Cerebelly Chief Science Officer.

  • What's next for Purdue Pharma after filing for bankruptcy
    Yahoo Finance Video

    What's next for Purdue Pharma after filing for bankruptcy

    Oxycontin maker Purdue Pharma filed for chapter 11 bankruptcy on Sunday, after reaching a tentative settlement with 24 states that accused the company of fueling the U.S. opioid crisis. Yahoo Finance's Alexis Keenan reports. William Soilman, Chairman and CEO of the Accreditation Council for Medical Affairs, further discusses with Yahoo Finance's Adam Shapiro and Julie Hyman.

  • Barrons.com

    The Opioid Crisis Hits Home for Investors

    Litigation against health-care companies is reaching a critical juncture. Investors need to rethink their exposure to the drug supply chain.

  • Gilead, AbbVie Are Innovative, but May Be Underappreciated
    GuruFocus.com

    Gilead, AbbVie Are Innovative, but May Be Underappreciated

    Companies need to demonstrate they can be successful in new therapeutic areas Continue reading...

  • The New Capitalism Is Looking a Lot Like the Old Capitalism
    Bloomberg

    The New Capitalism Is Looking a Lot Like the Old Capitalism

    (Bloomberg) -- The Business Roundtable caused a stir last month by declaring the purpose of a corporation isn’t merely to generate returns for shareholders -- the group’s official line since 1997 -- but to care for all its stakeholders.The 300-word statement spurred speculation over how corporate America might change. Not much, apparently, if you listen to the chief executives themselves.Bloomberg News reached out to the 181 CEOs who signed the declaration. Roughly two dozen responded, with identical answers: Our companies are already run with customers, employees, suppliers and communities in mind. And shareholders, of course. Otherwise we’d have gone out of business long ago.Many even said they’ve operated that way for years, or even decades -- in other words, long before disillusionment with the global economy helped upend politics from Washington to London and beyond. And they rejected the notion that earning shareholders a fair return ends up short-changing other parties.Critics, though, point to gaping inequality, runaway executive pay and insufficient efforts to combat climate change as evidence that while some companies do better than others, the overall numbers can’t possibly bear out the CEOs’ claims.“I don’t know how you look at the current situation in the country and say: ‘We’re really killing it in terms of taking care of all our stakeholders,’” said Rick Wartzman, director of the Drucker Institute’s KH Moon Center for a Functioning Society, who discussed the matter with Roundtable Chairman Jamie Dimon over dinner last year. “There’s been a tremendous imbalance with shareholder value being put ahead of everyone else.”Several CEOs acknowledged that many Americans haven’t reaped the benefits of recent years’ economic expansion, and that the political discourse has made them think harder about what can be done to bring those people along. But some, including JPMorgan Chase & Co.’s Dimon, argue that corporations alone can’t solve all society’s problems and shouldn’t be blamed for its shortcomings.“I do think business can do more,” Dimon said. “But I don’t think business alone can do it.”In interviews, the men -- and they were all men -- spoke about a range of programs and initiatives undertaken to pay employees more, reduce their firms’ environmental footprint and support communities.“Most corporate CEOs feel that we serve each stakeholder best by serving all,” said Tom Linebarger, head of diesel-engine manufacturer Cummins Inc. and a Roundtable board member.Lawrence Kurzius of spice-maker McCormick & Co. spoke about his firm’s efforts to assist small farmers in developing countries. “The best companies, frankly, are not those who try to scrape every last dollar for the shareholder,” he said.Vistra Energy Corp.’s Curt Morgan pointed to the company’s employee bonus program and efforts to subsidize or waive utility bills for low-income families. “It was easy for us to sign” the Roundtable’s statement, he said, “because we were living it.”Marc Lautenbach of Pitney Bowes Inc. said the firm used half of the money saved thanks to the 2017 corporate tax cut to give employees a permanent raise. “You’ve got to get the balance right,” he added.Douglas Peterson of S&P Global Inc. listed his company’s paper reduction initiatives, carbon offsets and data science training for workers.Not everyone shares their view.Treasury Secretary Steven Mnuchin said at a New York Times conference this month he wouldn’t have signed the pledge because if companies only focus on purpose over profits, “you’re not going to have a very vibrant business community.”And Blackstone Group Inc.’s Steve Schwarzman -- one of a handful of Roundtable members who didn’t sign it -- said that while companies must consider stakeholders, focusing on all of them equally would make it difficult for him as a CEO to know what he’s supposed to do.“I look at this as a little bit of a red herring,” Schwarzman said.But Mark Sutton, CEO of International Paper Co., said his firm’s work sustaining forests and reducing emissions isn’t getting in the way of investor returns.“The shareholders are absolutely at the center,” Sutton said. “We’re just saying what was left unsaid but implied: You can’t keep the shareholder at the center if you’re not excellent with the other people affected by your company.”Even hardened skeptics have acknowledged that the Roundtable’s statement, if nothing else, was a step in the right direction. But some say that corporate-responsibility initiatives -- while important and well-intended -- won’t fundamentally change the chase for stock returns that still largely dictate corporate priorities.Take the more than $8 billion in 2018 charitable donations by firms overseen by the Roundtable’s roughly 200 members, which pales in comparison with the almost $400 billion the same companies spent on share buybacks that year.There’s also the question of how a company’s commitment to communities should be weighed against other aspects of its business.Johnson & Johnson, whose CEO Alex Gorsky led the committee that wrote the Roundtable’s new statement, has donated medicine that has helped treat over 100 million children, a spokesman said. But one week after the Roundtable’s new corporate credo was published on Aug. 19, an Oklahoma judge found J&J liable for fueling the state’s opioid crisis and ordered it to pay a $572 million fine. Gorsky declined to be interviewed for this story.“Johnson & Johnson did not cause the opioid crisis in Oklahoma” and will appeal the verdict, said Ernie Knewitz, a company spokesman. “We are actively collaborating with several organizations to help patients, families and communities” and find solutions to the crisis.Given the economic realities many people face, burnishing the image of modern capitalism will take some work.Since 1973, real income for the median U.S. household has grown 0.4% annually, according to the Peterson Institute for International Economics. The S&P 500, meanwhile, has seen annual increases of 10% in that time, and CEOs in the index received on average $13.8 million in 2018. That’s about 300 times more than their median workers -- a ratio that’s multiplied in recent decades.Growing inequality helps explain why many young people in the U.S. are embracing ideas like universal health care and tuition-free college -- and why many people are skeptical that corporate priorities are really going to change.“If these CEOs aren’t going to back up their words with real action to help workers, their words are meaningless,” said Senator Elizabeth Warren, a Democratic candidate for the presidency, who’s proposed making companies legally required to look out for all major stakeholders. “We need fundamental change now.”(Updates with J&J comment in 25th paragraph.)\--With assistance from Olivia Carville, Thomas Black, Jenny Surane, Matt Townsend, Richard Clough, Jordyn Holman, David Welch, Michelle F. Davis, Annie Massa, Riley Griffin, John Tozzi, Michelle Fay Cortez, Keith Naughton, Ian King, Nico Grant, Rachel Adams-Heard, Katherine Chiglinsky, Gerry Smith, Julie Johnsson, Matt Day, Cynthia Koons, Craig Giammona, Sonali Basak, Lananh Nguyen, Justin Bachman, Oliver Sachgau, Kelly Gilblom, Anousha Sakoui, Brandon Kochkodin, Sridhar Natarajan, Kevin Crowley, Mary Schlangenstein, Scott Moritz, Heather Perlberg, Matthew Boyle and Robert Langreth.To contact the reporter on this story: Anders Melin in New York at amelin3@bloomberg.netTo contact the editors responsible for this story: Pierre Paulden at ppaulden@bloomberg.net, Steven CrabillFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Broadcom, Anthem and Allstate
    Zacks

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Broadcom, Anthem and Allstate

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Broadcom, Anthem and Allstate

  • Trovagene's Onvansertib Shows Response in Phase Ib AML Study
    Zacks

    Trovagene's Onvansertib Shows Response in Phase Ib AML Study

    Trovagene (TROV) successfully completes a phase Ib study, evaluating onvansertib in combination with standard-of-care in AML patients. The regimen is well tolerated and safe.

  • MarketWatch

    Walgreens Boots, Pfizer share gains contribute to Dow's nearly 75-point jump

    DOW UPDATE Shares of Walgreens Boots and Pfizer are seeing strong returns Friday morning, propelling the Dow Jones Industrial Average into positive territory. Shares of Walgreens Boots (WBA) and Pfizer (PFE) are contributing to the blue-chip gauge's intraday rally, as the Dow (DJIA) was most recently trading 72 points, or 0.

  • Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates
    Zacks

    Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates

    FDA approves label expansion of Merck's (MRK) Keytruda and J&J's (JNJ) Erleada.

  • Bull of the Day: Amgen (AMGN)
    Zacks

    Bull of the Day: Amgen (AMGN)

    Bull of the Day: Amgen (AMGN)

  • Johnson & Johnson Could Shrug Off Pressure In Third Quarter — Here's Why
    Investor's Business Daily

    Johnson & Johnson Could Shrug Off Pressure In Third Quarter — Here's Why

    Johnson & Johnson stock remains under pressure from various lawsuits, but on Thursday an analyst called for the Dow Jones pharmaceutical company to report outsized third-quarter results.

  • Top Stock Reports for Johnson & Johnson, Boeing & Broadcom
    Zacks

    Top Stock Reports for Johnson & Johnson, Boeing & Broadcom

    Top Stock Reports for Johnson & Johnson, Boeing & Broadcom

  • J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use
    Zacks

    J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use

    J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.

  • Barrons.com

    Johnson & Johnson Stock Is Going to Rise Despite Opioid Lawsuits, Analyst Says

    Things are looking sunny for Johnson & Johnson, according to a new analysis from Credit Suisse analyst Matt Miksic.

  • FDA Warns About Safety of Breast Implant: 3 Stocks at Risk
    Zacks

    FDA Warns About Safety of Breast Implant: 3 Stocks at Risk

    As breast implant-related health hazards surface, a few manufacturing companies might bear a brunt.

  • Reuters

    UPDATE 1-GSK's over-the-counter nicotine oral spray gets FDA panel backing

    An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc's over-the-counter nicotine oral spray that aims to help smokers quit their addiction. The panel voted 9-6 in favor of the therapy, saying its benefits as a smoking cessation aid outweighed risks. The FDA usually follows the recommendations of its experts, but is not mandated to do so.

  • Johnson & Johnson to Host Investor Conference Call on Third Quarter Results
    PR Newswire

    Johnson & Johnson to Host Investor Conference Call on Third Quarter Results

    The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.

  • Establishment Labs Poised to Capitalize on Allergan Breast Implant Issues
    GuruFocus.com

    Establishment Labs Poised to Capitalize on Allergan Breast Implant Issues

    Costa Rican company’s technology believed to cause fewer complications Continue reading...

  • Are You Looking for a High-Growth Dividend Stock? Johnson & Johnson (JNJ) Could Be a Great Choice
    Zacks

    Are You Looking for a High-Growth Dividend Stock? Johnson & Johnson (JNJ) Could Be a Great Choice

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

  • Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
    Zacks

    Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $129.64, moving +0.08% from the previous trading session.

  • Should You Buy Vegan Stocks & ETF?
    Zacks

    Should You Buy Vegan Stocks & ETF?

    Beyond Meat is one of the hottest IPOs this year and a new ETF aims to capitalize on the trend.

  • Novartis Announces New Data on Spondylitis Drug Cosentyx
    Zacks

    Novartis Announces New Data on Spondylitis Drug Cosentyx

    Novartis (NVS) announces new positive data from a phase III study on Cosentyx in patients with active nr-axSpA.

  • Karyopharm Signs $150M Royalty Agreement to Support Xpovio
    Zacks

    Karyopharm Signs $150M Royalty Agreement to Support Xpovio

    Karyopharm (KPTI) signs royalty agreement with HealthCare Royalty Partners for up to $150 million to fund Xpovio's commercialization and development.

  • J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis
    Zacks

    J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis

    J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.

  • S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels
    PR Newswire

    S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels

    - Q2 2019 share repurchases were $164.5 billion - 20.1% lower than Q1 2019, 13.7% lower than Q2 2018, and 26.2% lower than the record Q4 2018. - Apple continues to lead, spending $18.2 billion - down from ...